ArticleOncoimmunology
PD-1 expression conditions T cell avidity within an antigen-specific repertoire.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 70 citations in OpenAlex.
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- PINK1 deficiency rewires early immune responses in a mouse model of Parkinson's disease triggered by intestinal infection.NPJ Parkinson's disease · 2025Article
- The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy.Advanced functional materials · 2024Article
- The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma.bioRxiv : the preprint server for biology · 2024Article
- Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1.Journal for immunotherapy of cancer · 2024Article
- Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity.Cell communication and signaling : CCS · 2024Article
- Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.BMC immunology · 2024Article
- Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.Oncoimmunology · 2024Article
- Interferon-γ couples CD8Nature communications · 2023Article
- Selection of highly responsive T cell receptors by an analysis combining the expression of multiple markers.Cancer science · 2023Article
- Article
- Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.Oncoimmunology · 2022Article
- Human cytomegalovirus expands a CD8Science immunology · 2021Article
- Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.Oncoimmunology · 2021Article
- CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer.Translational lung cancer research · 2020Article
- Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.Blood cancer journal · 2020Article
- Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.Oncoimmunology · 2020Article
- Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.Journal of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its negative regulatory role on tumor-specific T cells, Programmed cell death 1 (PD-1) is also a marker of activated tumor-infiltrating T cells. In cancer, PD-1 blockade partially reverses T cell dysfunction allowing the amplification of tumor reactive T cells. Here, we investigated the role of PD-1 signaling on effector/memory human T cells specific for shared melanoma antigens, derived from blood. We documented for the first time the existence of melanoma-specific T cell clones unable to express PD-1. This stable feature was due to the persistent methylation of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.